We are thrilled to announce our participation in the 13th Alzheimer’s & Parkinson’s Drug Development Summit as a solution provider and preclinical CRO expert in AD’s and PD’s disease studies. This summit is a unique opportunity to unite new faces across biotech and pharma, capitalize on groundbreaking progress, and accelerate the development of transformative neurodegenerative therapies.
📅 If you’re attending the conference, book a meeting with Jérome BERNARD who will be in Boston all the week by clicking here.
Let’discover ETAP-Lab’s dedicated lab for neuroscience expertise with:
– cellular models, dealing with proteinopathies with our own oligomers | Neuronal injuries with chemical toxins| Brain-on-chip | Advanced High-Content Screening
– efficacy models, β-amyloidopathy with proprietary oligomers|Behavioral expertise and Translational approach | Bioassays & histology platform.
Join us as we engage with innovative presentations on:
- Novel targets beyond Aβ
- Deciphering disease complexity
- Enhancing α-synuclein detection
- Advancing blood-based biomarkers
We look forward to listening to pioneering insights from industry leaders and contributing to the collaborative atmosphere aimed at spearheading the next wave of neurodegenerative therapeutics.
